Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Kedudukan dalam Saham #16882
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Harga Saham
$2.52
Modal Pasaran
$274.65M
Perubahan (1 hari)
0.46%
Perubahan (1 tahun)
-56.11%
Negara
CN
Perdagangan VISEN Pharmaceuticals (2561)

Kategori

Sejarah pecahan saham untuk VISEN Pharmaceuticals (2561)
Saham VISEN Pharmaceuticals (simbol: 2561) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Sep 02, 2026.
Satu saham 2561 yang dibeli sebelum Sep 02, 2026 kini bersamaan dengan 0 saham 2561.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa